



(51) International Patent Classification:

C07H 21/02 (2006.01) C12N 15/11 (2006.01)
C07H 1/04 (2006.01) C12N 15/10 (2006.01)

(21) International Application Number:

PCT/US2023/061255

(22) International Filing Date:

25 January 2023 (25.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/267,223 27 January 2022 (27.01.2022) US
63/382,956 09 November 2022 (09.11.2022) US
63/476,787 22 December 2022 (22.12.2022) US

(71) Applicant: **TRILINK BIOTECHNOLOGIES, LLC**
[US/US]; 10770 Wateridge Circle, Suite 200, San Diego,
CA 92121 (US).

(72) Inventors: **XU, Chunping**; c/o TriLink BioTechnologies,
LLC, 10770 Wateridge Circle, Suite 200, San Diego, CA
92121 (US). **HOUSTON, Michael**; c/o TriLink BioTech-

nologies, LLC, 10770 Wateridge Circle, Suite 200, San
Diego, CA 92121 (US). **LEBEDEV, Alexandre**; c/o
TriLink BioTechnologies, LLC, 10770 Wateridge Circle,
Suite 200, San Diego, CA 92121 (US). **HENDERSON,
Jordana, Michelle**; c/o TriLink BioTechnologies, LLC,
10770 Wateridge Circle, Suite 200, San Diego, CA 92121
(US). **UJITA, Andrew**; c/o TriLink BioTechnologies,
LLC, 10770 Wateridge Circle, Suite 200, San Diego,
CA 92121 (US). **KOUKHAREVA, Inna**; c/o TriLink
BioTechnologies, LLC, 10770 Wateridge Circle, Suite
200, San Diego, CA 92121 (US). **ZHAO, Chanfeng**; c/o
TriLink BioTechnologies, LLC, 10770 Wateridge Circle,
Suite 200, San Diego, CA 92121 (US). **ILICHEV, Ilya,
Vladimirovich**; c/o TriLink BioTechnologies, LLC, 10770
Wateridge Circle, Suite 200, San Diego, CA 92121 (US).

(74) Agent: **DAVIS, Kimberlynn, B.**; Kilpatrick Townsend &
Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree
Street, N.E., Suite 2800, Atlanta, GA 30309 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,

(54) Title: TRINUCLEOTIDE CAP ANALOGS AND METHODS OF USE THEREOF




FIGURE 1

(57) Abstract: Described herein are novel trinucleotide cap analogs and methods of making and using the same. Also described herein is an RNA molecule comprising a 5'-cap, wherein the 5'-cap includes a trinucleotide cap analog as described herein. Methods of inducing a therapeutic effect in a 5 subject are also described herein, the methods including a step of administering to the subject an RNA molecule including the trinucleotide cap analog.

[Continued on next page]

DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*